China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics, an RNA drug developer. The collaboration will focus on mRNA raw materials, lipid chemistry, lipid nanoparticle (LNP) technology, and complex preparations, among other areas. Financial details of the agreement have not been disclosed.
Synthgene and Starna aim to leverage their respective technological strengths in mRNA raw materials and LNP delivery technology platforms to advance the application of mRNA and other nucleic acid products in the fields of infectious disease vaccines, gene editing, and autologous cell therapy.- Flcube.com
